Trial reportCancer immunology, immunotherapy : CII2012
Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer.
Trial report in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 62 citations in OpenAlex.
- Leptin/LPS-treated dendritic cells reduce the expression of genes involved in tumor tissue metastasis and angiogenesis in an animal model of breast cancer.Immunologic research · 2024Article
- Review
- Dendritic Cells in Cancer Immunology and Immunotherapy.Cancers · 2024Review
- Update on current and new potential immunotherapies in breast cancer, from bench to bedside.Frontiers in immunology · 2024Review
- Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies.Biomedicines · 2023Article
- Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors.NPJ breast cancer · 2022Review
- Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.Frontiers in oncology · 2022Review
- Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making.Journal of personalized medicine · 2021Review
- Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.Cancer metastasis reviews · 2021Review
- Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis.Therapeutic advances in medical oncology · 2021Article
- The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines.Vaccines · 2020Review
- Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine.Frontiers in oncology · 2020Review
- Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer.Journal of breast cancer · 2018Review
- Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?Vaccines · 2018Review
- Exosomes derived from rAAV/AFP-transfected dendritic cells elicit specific T cell-mediated immune responses against hepatocellular carcinoma.Cancer management and research · 2018Article
- Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.Oncotarget · 2017Article
- Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8Clinical & translational immunology · 2017Article
- Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma.Science translational medicine · 2017Article
- Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results.OncoTargets and therapy · 2016Article
- Natural killer cells as helper cells in dendritic cell cancer vaccines.Frontiers in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA wealth of preclinical information, as well as a modest amount of clinical information, indicates that dendritic cell vaccines have therapeutic potential. The aim of this work was to assess the immune response, disease progression, and post-treatment survival of ER/PR double-negative stage II/IIIA breast cancer patients vaccinated with autologous dendritic cells pulsed with autologous tumor lysates.
methodsDendritic cell (DC) vaccines were generated from CD14+ precursors pulsed with autologous tumor lysates. DCs were matured with defined factors that induced surface marker and cytokine production. Individuals were immunized intradermally four times. Specific delayed type IV hypersensitivity (DTH) reaction, ex vivo cytokine production, and lymphocyte subsets were determined for the evaluation of the therapeutic efficiency. Overall survival and disease progression rates were analyzed using Kaplan–Meier curves and compared with those of contemporaneous patients who were not administered DC vaccines.
resultsThere were no unanticipated or serious adverse effects. DC vaccines elicited Th1 cytokine secretion and increased NK cells, CD8+ IFN-+ cells but decreased the percentage of CD3+ T cells and CD3+ HLA-DR+ T cells in the peripheral blood. Approximately 58% (18/31) of patients had a DTH-positive reaction. There was no difference in overall survival between the patients with and without DC vaccine. The 3-year progression-free survival was significantly prolonged: 76.9% versus 31.0% (with vs. without DC vaccine, p < 0.05).
conclusionOur findings strongly suggest that tumor lysate-pulsed DCs provide a standardized and widely applicable source of breast cancer antigens that are very effective in evoking anti-breast cancer immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.